LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

YHLO Launches New SARS-CoV-2 Neutralization Antibody (NAb) Assay

By LabMedica International staff writers
Posted on 03 Mar 2021
Print article
Illustration
Illustration
Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China) has launched its new SARS-CoV-2 NAb test kit designed to detect all antibodies that are able to inhibit the binding between S1 RBD and ACE2 in both CLIA and FIA platforms.

The test is intended to be used for the evaluation of neutralization antibodies in discharged patients, monitor neutralization antibodies in people who had COVID-19 vaccination, and the efficacy of immunotherapy. Neutralization antibody assay is essential for many vaccines and treatments for other infectious diseases, e.g. Anti-HBs assay is measuring neutralization antibody of Hepatitis B Virus. By definition, neutralization antibodies against SARS-CoV-2 can stop COVID-19 Receptor Binding Domain (RBD) from binding to Angiotensin-Converting Enzyme 2 (ACE2) receptor in human cells, which prevent SARS-CoV-2 to invade human cells.

When compared to traditional PRNT and ELISA test, YHLO’s SARS-CoV-2 NAb test kit offers the distinct advantage of being a quantitative test on the CLIA/FIA platform, which provides valuable clinical data to any studies that intend to assess either immune response or therapy efficacy in COVID-19. Additionally, the use of the CLIA/FIA method drastically improves testing capacity and efficiency, aiding the large-scale study on NAb.

Some additional advantages offered by YHLO’s SARS-CoV-2 NAb test kit include quantitative test yielding data with medical value, high throughput with short TAT (first result <30 minutes), full automation which minimizes human-induced error, cost-effectiveness and lower labor intensity, and a dynamic design that mimics the human body internal environment.



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.